To Our Investors

PSS deeply appreciates your support to us. We would like to express our heartfelt sympathy to those who have suffered from the Great East Japan Earthquake on March 11, 2011. Here is summary of PSS business results of last fiscal year and business prospect for the current fiscal year;

1. PSS contribution to society by growing its business

 Ultimately, our business goal is to make human daily life more comfortable through supplying more practical and usable molecular diagnostics systems. This can be realized by introducing fully automated instruments, on which PSS has been focused by bringing manufacturing expertise into biotechnology fields.

2. Responding to changes in social needs

 The market environment has dramatically changed in 10 years since our IPO of Feb 28, 2001, in which, an aging society with fewer children in the developed countries emerged as typically seen in Japan. As a result, the social cost, such as healthcare, pension, etc. could increase further in the future; in this context, introduction of more cost effective diagnostics system is socially demanded. Molecular diagnostics system is viewed particularly effective in; such as, pharmacogenomics, which enables to evaluate effectiveness and counter-effect of certain medicines for individual patients, resulting in prevention of useless or harmful prescription as well as earlier detection of cancer and infectious diseases.

3. Diagnostic systems that PSS seeks

 PSS has supplied its original products (automated DNA extractors and plastic consumables, exclusively used for the instruments) to the worldwide market as OEM products of globally respected partners. Based on our experience in automated system and understanding of social needs, we have successfully developed original automated analyzers, which can diagnose by merely pushing a button. We are trying hard to introduce the instruments to the market as early as possible.

4. Business results of previous fiscal year & prospect for this year

 The business results in the fiscal year ended June 30, 2011 was very slow mostly because the demand for our products decreased as rush of investment in the previous year related to world-wide outbreak of swine flu had been disappeared and large inventory left in our OEM partners.
We take the results seriously and we must strictly manage our business according to the following management guidelines with organization reform;

1. 1. Establishment of growth models by bringing new break-through products into the market as early as possible

⇒ Integration of PSS original technologies: Fully automated system

2. 2. Increase of the earning capacity of existing business

⇒ Improvement of return on sales: Further pursuit of manufacturing expertise
(Not only cost down, but also adding more value to the end user)

3. 3. Decrease sales and administrative cost

⇒ Maximization of profitability

5. Finally

 The business field of molecular diagnostic, where PSS has been engaged, is rapidly expanding and expected to accelerate in the near future. By understanding and evaluating how PSS technologies are most effectively applied in actual diagnostic market, we will accomplish our plan, and soon present you, our shareholders and investors, fruitful results that would meet your expectation.
We are looking forward to your continued support.